Baseline variables | Model 1 | Model 2 | ||||
---|---|---|---|---|---|---|
OR | (95% CI) | P | OR | (95% CI) | P | |
Antiemotionality (RCF score*) | 1.40 | (1.05-1.87) | .023 | 1.47 | (1.07-2.00) | .016 |
ACR class | 10.52 | (5.87-18.9) | <.001 | 6.13 | (3.17-11.8) | <.001 |
Female sex | 1.92 | (0.53-6.98) | .32 | |||
Age | 1.00 | (0.96-1.04) | .99 | |||
Joint stage* | 1.20 | (0.80-1.78) | .38 | |||
Afflicted joints* count | 1.03 | (1.00-1.07) | .06 | |||
No. extra-articular complications* | 1.40 | (0.96-2.02) | .08 | |||
Log. C-reactive protein | 1.30 | (0.99-1.71) | .06 | |||
Methotrexate use | 1.39 | (0.67-2.88) | .38 | |||
Corticosteroids use | 0.43 | (0.20-0.94) | .034 | |||
Other DMARDs use | 1.12 | (0.54-2.32) | .76 | |||
Education level | 0.80 | (0.52-1.23) | .30 |